CL2014000543A1 - Compuestos derivados de imidazopiridazinas sustituidas con amino, inhibidores de la quinasa ,mknk2; metodo de preparacion; compuestos intermediarios y su uso; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento del cancer. - Google Patents
Compuestos derivados de imidazopiridazinas sustituidas con amino, inhibidores de la quinasa ,mknk2; metodo de preparacion; compuestos intermediarios y su uso; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento del cancer.Info
- Publication number
- CL2014000543A1 CL2014000543A1 CL2014000543A CL2014000543A CL2014000543A1 CL 2014000543 A1 CL2014000543 A1 CL 2014000543A1 CL 2014000543 A CL2014000543 A CL 2014000543A CL 2014000543 A CL2014000543 A CL 2014000543A CL 2014000543 A1 CL2014000543 A1 CL 2014000543A1
- Authority
- CL
- Chile
- Prior art keywords
- compounds
- mknk2
- cancer
- preparation
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Cosmetics (AREA)
- Fats And Perfumes (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11180129 | 2011-09-06 | ||
| EP11182440 | 2011-09-23 | ||
| EP12179902 | 2012-08-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2014000543A1 true CL2014000543A1 (es) | 2014-09-26 |
Family
ID=47831558
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2014000543A CL2014000543A1 (es) | 2011-09-06 | 2014-03-06 | Compuestos derivados de imidazopiridazinas sustituidas con amino, inhibidores de la quinasa ,mknk2; metodo de preparacion; compuestos intermediarios y su uso; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento del cancer. |
Country Status (36)
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9730929B2 (en) | 2011-06-01 | 2017-08-15 | Bayer Intellectual Property Gmbh | Substituted aminoimidazopyridazines |
| UA117092C2 (uk) | 2011-09-06 | 2018-06-25 | Байєр Інтеллектуал Проперті Гмбх | Амінозаміщені імідазопіридазини |
| JP6174586B2 (ja) * | 2011-09-23 | 2017-08-02 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | 置換イミダゾピリダジン |
| ES2650915T3 (es) | 2011-12-12 | 2018-01-23 | Bayer Intellectual Property Gmbh | Imidazopiridazinas amino-sustituidas |
| JP6173426B2 (ja) * | 2012-03-29 | 2017-08-02 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | アミノ置換イミダゾピリダジン |
| CN104321326B (zh) | 2012-04-04 | 2017-05-31 | 拜耳医药股份有限公司 | 氨基取代的咪唑并哒嗪 |
| US9783543B2 (en) | 2012-11-19 | 2017-10-10 | Bayer Pharma Aktiengesellschaft | Aminoimidazopyridazines |
| EP2943485B1 (en) | 2013-01-14 | 2017-09-20 | Incyte Holdings Corporation | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors |
| HUE050215T2 (hu) | 2013-01-15 | 2020-11-30 | Incyte Holdings Corp | Pim kináz inhibitorokként hasznos tiazolkarboxamid és piridinkarboxamid vegyületek |
| EP2951181A1 (en) | 2013-01-30 | 2015-12-09 | Bayer Pharma Aktiengesellschaft | Amidoimidazopyridazines as mknk-1 kinase inhibitors |
| JP2016509036A (ja) * | 2013-02-20 | 2016-03-24 | バイエル・ファルマ・アクティエンゲゼルシャフト | Ｍｋｎｋ１阻害剤としての置換イミダゾ［１，２−ｂ］ピリダジン |
| TW201605866A (zh) | 2013-08-23 | 2016-02-16 | 英塞特公司 | 可用作ｐｉｍ激酶抑制劑之呋喃并－及噻吩并－吡啶甲醯胺化合物 |
| EP3092242A1 (en) | 2014-01-09 | 2016-11-16 | Bayer Pharma Aktiengesellschaft | Amido-substituted imidazopyridazines useful in the treatment of hyper-proliferative and/or angiogenesis disorders |
| WO2016010897A1 (en) | 2014-07-14 | 2016-01-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| JP2018500344A (ja) * | 2014-12-23 | 2018-01-11 | バイエル・ファルマ・アクティエンゲゼルシャフト | ６−ヒドロキシベンゾフラニル置換および６−アルコキシベンゾフラニル置換イミダゾピリダジン |
| DK3285809T3 (da) | 2015-04-20 | 2019-11-18 | Effector Therapeutics Inc | Inhibitorer af immunkontrolpunktsmodulatorer til anvendelse i behandling af kræft og infektioner. |
| US9540347B2 (en) | 2015-05-29 | 2017-01-10 | Incyte Corporation | Pyridineamine compounds useful as Pim kinase inhibitors |
| TWI734699B (zh) | 2015-09-09 | 2021-08-01 | 美商英塞特公司 | Ｐｉｍ激酶抑制劑之鹽 |
| WO2017059251A1 (en) | 2015-10-02 | 2017-04-06 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| US20170191136A1 (en) * | 2015-12-31 | 2017-07-06 | Effector Therapeutics, Inc. | Mnk biomarkers and uses thereof |
| WO2017157418A1 (en) | 2016-03-15 | 2017-09-21 | Bayer Pharma Aktiengesellschaft | Combination of mknk1-inhibitors |
| WO2019113487A1 (en) | 2017-12-08 | 2019-06-13 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4408047A (en) | 1980-03-28 | 1983-10-04 | Merck & Co., Inc. | Imidazodiazines |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| FR2619818B1 (fr) | 1987-09-01 | 1990-01-12 | Sanofi Sa | Imidazo (1,2-b) pyridazines, procede pour leur preparation et compositions pharmaceutiques les contenant |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| CA2458131A1 (en) | 2001-08-23 | 2003-03-06 | Takeda Chemical Industries, Ltd. | Jnk activation inhibitor |
| WO2007013673A1 (en) | 2005-07-29 | 2007-02-01 | Astellas Pharma Inc. | Fused heterocycles as lck inhibitors |
| WO2007025090A2 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase |
| DE102005042742A1 (de) | 2005-09-02 | 2007-03-08 | Schering Ag | Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
| US7750000B2 (en) | 2005-09-02 | 2010-07-06 | Bayer Schering Pharma Ag | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments |
| WO2007033080A2 (en) | 2005-09-12 | 2007-03-22 | Emory University | Alzheimer's disease imaging agents |
| DE102006029447A1 (de) | 2006-06-21 | 2007-12-27 | Bayer Schering Pharma Ag | Oxo-substituierte Imidazo[1,2b]pyridazine, deren Herstellung und Verwendung als Arzneimittel |
| ATE456565T1 (de) | 2006-06-22 | 2010-02-15 | Biovitrum Ab Publ | Pyridin- und pyrazinderivate als mnk- kinaseinhibitoren |
| US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| EP1900739A1 (en) * | 2006-08-30 | 2008-03-19 | Cellzome Ag | Diazolodiazine derivatives as kinase inhibitors |
| JP2010502716A (ja) * | 2006-09-07 | 2010-01-28 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | インターロイキン１受容体関連キナーゼの調節物質 |
| CA2667962A1 (en) | 2006-10-30 | 2008-05-08 | Novartis Ag | Heterocyclic compounds as antiinflammatory agents |
| US7750007B2 (en) | 2006-11-06 | 2010-07-06 | Supergen, Inc. | Imidazo[1,2-beta]pyridazine and pyrazolo[1,5-alpha]pyrimidine derivatives and their use as protein kinase inhibitors |
| WO2008072682A1 (ja) | 2006-12-15 | 2008-06-19 | Daiichi Sankyo Company, Limited | イミダゾ［１，２－ｂ］ピリダジン誘導体 |
| AR064420A1 (es) | 2006-12-21 | 2009-04-01 | Alcon Mfg Ltd | Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop). |
| PA8792501A1 (es) | 2007-08-09 | 2009-04-23 | Sanofi Aventis | Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met. |
| EP2217601A1 (en) | 2007-11-08 | 2010-08-18 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Imidazopyridazines for use as protein kinase inhibitors |
| BRPI0822240A2 (pt) | 2007-12-21 | 2015-06-30 | Wyeth Llc | Composto imidazo [1,2-b] piridazina como moduladores de receptores x hepáticos |
| CA2836203A1 (en) * | 2011-05-17 | 2012-11-22 | Bayer Intellectual Property Gmbh | Amino-substituted imidazopyridazines as mknk1 kinase inhibitors |
| US9730929B2 (en) | 2011-06-01 | 2017-08-15 | Bayer Intellectual Property Gmbh | Substituted aminoimidazopyridazines |
| HK1197063A1 (en) | 2011-06-22 | 2015-01-02 | 拜耳知识产权有限责任公司 | Heterocyclyl aminoimidazopyridazines |
| AR087701A1 (es) | 2011-08-31 | 2014-04-09 | Japan Tobacco Inc | Derivados de pirazol con actividad inhibidora de sglt1 |
| JO3192B1 (ar) | 2011-09-06 | 2018-03-08 | Novartis Ag | مركب بنزوثيازولون |
| UA117092C2 (uk) | 2011-09-06 | 2018-06-25 | Байєр Інтеллектуал Проперті Гмбх | Амінозаміщені імідазопіридазини |
| US9353081B2 (en) | 2011-09-23 | 2016-05-31 | Hoffmann-La Roche Inc. | Bicyclic dihydroquinoline-2-one derivatives |
| JP6174586B2 (ja) | 2011-09-23 | 2017-08-02 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | 置換イミダゾピリダジン |
| ES2650915T3 (es) | 2011-12-12 | 2018-01-23 | Bayer Intellectual Property Gmbh | Imidazopiridazinas amino-sustituidas |
| JP6173426B2 (ja) | 2012-03-29 | 2017-08-02 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | アミノ置換イミダゾピリダジン |
| CN104321326B (zh) | 2012-04-04 | 2017-05-31 | 拜耳医药股份有限公司 | 氨基取代的咪唑并哒嗪 |
| US9783543B2 (en) | 2012-11-19 | 2017-10-10 | Bayer Pharma Aktiengesellschaft | Aminoimidazopyridazines |
| EP2951181A1 (en) | 2013-01-30 | 2015-12-09 | Bayer Pharma Aktiengesellschaft | Amidoimidazopyridazines as mknk-1 kinase inhibitors |
| JP2016509036A (ja) | 2013-02-20 | 2016-03-24 | バイエル・ファルマ・アクティエンゲゼルシャフト | Ｍｋｎｋ１阻害剤としての置換イミダゾ［１，２−ｂ］ピリダジン |
| EP3092242A1 (en) | 2014-01-09 | 2016-11-16 | Bayer Pharma Aktiengesellschaft | Amido-substituted imidazopyridazines useful in the treatment of hyper-proliferative and/or angiogenesis disorders |
-
2012
- 2012-05-09 UA UAA201403426A patent/UA117092C2/uk unknown
- 2012-09-05 MY MYPI2014700492A patent/MY168413A/en unknown
- 2012-09-05 ES ES12761564.9T patent/ES2638319T3/es active Active
- 2012-09-05 DK DK12761564.9T patent/DK2758401T3/en active
- 2012-09-05 MX MX2014002697A patent/MX348064B/es active IP Right Grant
- 2012-09-05 BR BR112014004687A patent/BR112014004687A2/pt not_active IP Right Cessation
- 2012-09-05 CA CA2847514A patent/CA2847514A1/en not_active Abandoned
- 2012-09-05 WO PCT/EP2012/067264 patent/WO2013034570A1/en not_active Ceased
- 2012-09-05 RS RS20170812A patent/RS56179B1/sr unknown
- 2012-09-05 KR KR1020147008395A patent/KR20140059268A/ko not_active Ceased
- 2012-09-05 LT LTEP12761564.9T patent/LT2758401T/lt unknown
- 2012-09-05 SG SG11201400219PA patent/SG11201400219PA/en unknown
- 2012-09-05 EP EP12761564.9A patent/EP2758401B1/en active Active
- 2012-09-05 AP AP2014007496A patent/AP2014007496A0/xx unknown
- 2012-09-05 PL PL12761564T patent/PL2758401T3/pl unknown
- 2012-09-05 US US14/342,977 patent/US9499547B2/en not_active Expired - Fee Related
- 2012-09-05 SI SI201231035T patent/SI2758401T1/sl unknown
- 2012-09-05 CN CN201280047525.XA patent/CN103958515B/zh not_active Expired - Fee Related
- 2012-09-05 PE PE2014000307A patent/PE20141593A1/es not_active Application Discontinuation
- 2012-09-05 ME MEP-2017-191A patent/ME02951B/me unknown
- 2012-09-05 JP JP2014528955A patent/JP6174583B2/ja not_active Expired - Fee Related
- 2012-09-05 HR HRP20171248TT patent/HRP20171248T1/hr unknown
- 2012-09-05 PT PT127615649T patent/PT2758401T/pt unknown
- 2012-09-05 AU AU2012306422A patent/AU2012306422B2/en not_active Ceased
- 2012-09-05 EA EA201400311A patent/EA025688B1/ru not_active IP Right Cessation
- 2012-09-05 PH PH1/2014/500501A patent/PH12014500501A1/en unknown
-
2014
- 2014-03-05 MA MA36793A patent/MA35422B1/fr unknown
- 2014-03-06 CL CL2014000543A patent/CL2014000543A1/es unknown
- 2014-03-06 CR CR20140113A patent/CR20140113A/es unknown
- 2014-03-06 CO CO14048372A patent/CO6900146A2/es unknown
- 2014-03-06 EC ECSP14013231 patent/ECSP14013231A/es unknown
- 2014-03-06 GT GT201400043A patent/GT201400043A/es unknown
- 2014-03-06 DO DO2014000051A patent/DOP2014000051A/es unknown
- 2014-03-06 IL IL231351A patent/IL231351A/en not_active IP Right Cessation
- 2014-04-04 ZA ZA2014/02498A patent/ZA201402498B/en unknown
-
2017
- 2017-08-23 CY CY20171100892T patent/CY1119433T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2014000543A1 (es) | Compuestos derivados de imidazopiridazinas sustituidas con amino, inhibidores de la quinasa ,mknk2; metodo de preparacion; compuestos intermediarios y su uso; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento del cancer. | |
| CL2014002873A1 (es) | Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer. | |
| CL2014001547A1 (es) | Compuestos derivados de benzotienilo-pirrolotriazina, como inhibidores de la proteina tirosina quinasa; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para el tratamiento y/o la prevencion de cancer y enfermedades tumorales. | |
| CL2012003415A1 (es) | Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer . | |
| CL2014001103A1 (es) | Compuestos derivados de heteroaril piridona y aza-piridona sustituidas, inhibidores de btk quinasa; composicion farmaceutica que los comprende; proceso de preparacion de la composicion farmaceutica; kit farmaceutico; y uso para el tratamiento de trastornos inmunes, cancer, inflamacion, trastornos neurologicos, entre otros. | |
| BR112015031475A2 (pt) | composto, composição farmacêutica, método para tratamento de uma doença ou condição, kit, e, uso de composto. | |
| BR112014010179A8 (pt) | composto, composição farmacêutica, uso de um composto, e, método para a profilaxia ou tratamento de um estado ou condição | |
| BR112014010206A2 (pt) | composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença | |
| CL2016001895A1 (es) | Compuestos | |
| BR112014010177A2 (pt) | composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença | |
| MX2016012097A (es) | Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cáncer. | |
| CL2015002932A1 (es) | Inhibidores de proteína quinasa | |
| CL2016002735A1 (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
| EA201591420A1 (ru) | Гетероарильные соединения и их применение | |
| CL2015001733A1 (es) | Compuestos derivados de lactamas fusionadas de arilo y heteroarilo, moduladores de ezh2; composicion farmaceutica que los comprende; uso del compuesto para el tratamiento del cancer. | |
| CL2015000295A1 (es) | Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades. | |
| CL2016001737A1 (es) | Derivados heterocíclicos bicíclicos como inhibidores de bromodominio | |
| BR112014011671A2 (pt) | composto, composição farmacêutica, método para o tratamento de uma doença ou condição, e, uso de um composto | |
| CL2014000746A1 (es) | Compuestos derivados de 3-pirimidin-4-il-oxazolidin-2-ona y sus sales, como inhibidores de las proteinas idh mutantes; composicion farmaceutica que los comprende, utiles para el tratamiento de trastornos de la proliferacion celular tal como el cancer. | |
| BR112015006019A2 (pt) | composto selecionado, composição farmacêutica, método para tratar uma doença ou distúrbio, uso de um composto, kit para tratar uma condição mediada por pim quinase e invenção. | |
| CL2012002189A1 (es) | Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos. | |
| CL2013003051A1 (es) | Compuestos derivados de pirazolo (4.3-d) pirimidinas, inhibidores de quinasa; composicion farmaceutica; y uso para el tratamiento de enfermedades y trastornos del aparato respiratorio | |
| BR112016000489A2 (pt) | composto, composição farmacêutica que o compreende, uso da composição e métodos para fabricar compostos | |
| CL2013001338A1 (es) | Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih. | |
| BR112015015891A8 (pt) | Composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica |